World Journal of Pharmacology and Toxicology

**Open Access** 

## Pharmacological Safety in Drug Development: Ensuring Efficacy with Minimal

## Arianna Briggs\* and John Jastapo

Bristol-Myers Squibb, Research and Development, USA

## Abstract

Pharmacological safety is a paramount consideration in the drug development process, aiming to strike a delicate balance between therapeutic e cacies and minimi:ing adverse e ects. This abstract provides an overview of the multifaceted aspects of pharmacological safet<sup>\*</sup>, emphasi:ing its crucial role in ensuring the successful translation of novel compounds from preclinical stages to clinical application. The initial phases of drug development involve rigorous preclinical testing to assess a compounds safet<sup>\*</sup> pro, le. Evaluating pharmacokinetics, toxicolog<sup>\*</sup>, and mechanisms of action in animal models aids in predicting potential human responses. The transition to clinical trials demands meticulous monitoring of safety parameters, necessitating comprehensive studies on dose-response relationships and potential interactions. Ensuring pharmacological safet<sup>\*</sup> is a d<sup>\*</sup>namic and evolving process, requiring collaboration between researchers, clinicians, and regulator<sup>\*</sup> bodies. Embracing innovative technologies and methodologies allows for more e cient identi, cation and mitigation of safet<sup>\*</sup> concerns throughout the drug development continuum. As the landscape of drug development continues to evolve, prioriti:ing pharmacological safet<sup>\*</sup> remains paramount to delivering e ective and well-tolerated therapeutics to patients worldwide.

- Dunham NW, Mi<sup>^</sup>a TS (1959) A note on a simple apparatus for detecting neurological de, cit in mice and rat. J Am Pharm Assoc 46: 208-209.
- 4. Drug dependenc<sup>^</sup> test, drug approval and licensing procedures in Japan 1997, Yakug<sup>^</sup>o Jiho Guideline Japan noti, cation no. 113. of the Narcotics Division, PAB dated March 14, 1975 and for complement noti, cation no. 383 of the Narcotics Division, PAB dated June 7, 1978. [12] FDA, Center for drug evaluation and research, division of drugs information. Assessment of abuse potential of drugs, Januar<sup>^</sup> 2010.
- Gianutsos G, Drawbaugh R, H<sup>^</sup>nes M, Lal H (1975) The narcotic withdrawal s<sup>^</sup>ndrome in the rat. In: Methods in narcotic research. New York: Marcel Dekker 293-309.
- 6. T:schentke T (1998) Measuring reward with the conditioned preference

paradigm: a comprehensive review of drug e ects, recent progress and new issues. Prog Neurobiol 56: 613-672.

- Colpaert FC (1999) Drug discrimination in neurobiolog<sup>^</sup>. Pharmacol Biochem Behav 64: 337-345.
- Ator NA, Gri ths RR (2003) Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend 70: 55-72.
- Monahan BP, Ferguson CL, Kileav<sup>^</sup> ES, Ll<sup>^</sup>od BK, Tr<sup>^</sup> J, et al. (1990) Torsades de pointes occurring in association with terfenadine use. JAMA 264: 2788-2790.
- Zimmerman M, Duru: H, Guinand O, Broccard O, Lev<sup>^</sup> P, et al. (1992) Torsades de pointes after treatment with terfenadine and ketocona:ole. Eur Heart J 13: 1002-1003.